ADMA Biologics has demonstrated a remarkable operational turnaround, with gross margins expanding from 47.8% in 2024Q1 to 69.4% in 2026Q2, driven by a favorable product mix shift toward premium ASCENIV sales.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | $0.23+16.9% vs $0.20 | $141M+2.2% vs $138M |
Q3 2026 Aug 5, 2026 | $0.16-2.0% vs $0.16 | $124M-0.8% vs $125M |
Q2 2026 May 6, 2026 | $0.19-1.7% vs $0.19 | $114M-18.2% vs $140M |
Q1 2026 Feb 25, 2026 | $0.20+8.1% vs $0.18 | $139M-0.3% vs $140M |
After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
From a technical perspective, Adma Biologics (ADMA) is looking like an interesting pick, as it just reached a key level of support. ADMA recently overtook the 200-day moving average, and this suggests a long-term bullish trend.
ADMA Biologics, Inc. (ADMA) Q3 2026 Earnings Call Transcript
Adma Biologics (ADMA) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.16 per share a year ago.
Benchmark ADMA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for ADMA Biologics, Inc. (ADMA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $12.73 | $2.95B | 15.76 | 19.63% | 35.14% | 42.56% | — | |
| $8.43 | $7.13B | 10.00 | 0.2% | 6.77% | 6.5% | 2.39% | |
| $381.57 | $10.27B | 10.05 | 0.65% | 39.45% | 14.07% | — | |
| $0.01 | $72.88K | -0.00 | -35.82% | -717.43% | -1358.66% | — | |
| $103.63 | $12.29B | 26.18 | 37.55% | 26.93% | 544.26% | — | |
| $375.74 | $15.2B | 20.71 | 0.33% | 13.78% | 44.18% | 1.12% |
ADMA Biologics, Inc. (ADMA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
ADMA Biologics, Inc. (ADMA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 2, 2026·SEC
May 6, 2026·SEC
Get notified when ADMA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ADMA Biologics, Inc. (ADMA) stock FAQ — growth, dividends, profitability & financials explained
ADMA Biologics, Inc. (ADMA) reported $519.2M in revenue over the trailing twelve months. Revenue was $510.2M in fiscal year 2025.
ADMA Biologics, Inc. (ADMA) grew revenue by 6.3% over the trailing twelve months, compared with the twelve months before.
Yes. ADMA Biologics, Inc. (ADMA) earned $182.4M in net income over the trailing twelve months (a 35.1% net margin).
ADMA Biologics, Inc. (ADMA) had a return on equity (ROE) of 42.6% over the trailing twelve months. That is well above the market's typical 10-15%.
ADMA Biologics, Inc. (ADMA) generated $132.9M in free cash flow over the trailing twelve months.
